

 Early Warning System

WB-P167064

HIV Vaccine Research and Development



## Quick Facts

Financial Institutions	World Bank (WB)
Status	Approved
Bank Risk Rating	B
Voting Date	2019-01-23
Sectors	Education and Health
Investment Amount (USD)	\$ 5.75 million
Project Cost (USD)	\$ 5.75 million



---

## Project Description

This project will finance HIV research and development for viable vaccine candidate(s) and other potential viral vectors. This project is not country-specific.



---

## Investment Description

- World Bank (WB)



---

## Contact Information

World Bank

Robert Oelrichs

Senior Health Specialist (Email contact not provided)

Borrower/Client/Recipient

International AIDS Vaccine Initiative

Mark Feinberg

President and CEO

mfeinberg@iavi.org

Implementing Agencies

International AIDS Vaccine Initiative

Mark Feinberg

President and CEO

mfeinberg@iavi.org

## ACCOUNTABILITY MECHANISM OF WORLD BANK

The World Bank Inspection Panel is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by a World Bank-financed project. If you submit a complaint to the Inspection Panel, they may investigate to assess whether the World Bank is following its own policies and procedures for preventing harm to people or the environment. You can contact the Inspection Panel or submit a complaint by emailing [ipanel@worldbank.org](mailto:ipanel@worldbank.org). You can learn more about the Inspection Panel and how to file a complaint at: <http://ewebapps.worldbank.org/apps/ip/Pages/Home.aspx>.



---

## Bank Documents

- [Concept Project Information Document-Integrated Safeguards Data Sheet - HIV Vaccine Research and Dev](#) [Original Source]